Full Press Release Details
Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer
PA and VANCOUVER, British Columbia, February 16, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast
cancer, announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO), effective today.
Del Priore will oversee the clinical and regulatory aspects of BriaCell's current and upcoming clinical trials including the ongoing
Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT , with Incyte's checkpoint inhibitors, retifanlimab
and epacadostat in advanced breast cancer.
are thrilled to welcome Dr. Del Priore to our leadership team. Dr. Del Priore is an accomplished senior executive with extensive clinical
expertise, depth of knowledge, key relationships, and an excellent track record of managing oncology clinical trials," commented
Dr. Bill Williams, BriaCell's President & CEO. "We look forward to his leadership and clinical trial related insights
as we advance the clinical development of our novel product candidates."
an Oncologist, I have witnessed the difficult decisions patients and doctors face every day in the absence of safe and effective treatments,"
said Dr. Del Priore. "BriaCell's data in advanced breast cancer patients, a very difficult patient population to treat, has
been impressive. I am very excited to join the BriaCell team to help accelerate development of these novel therapeutics to bring hope
to cancer patients with limited therapeutic options."
Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management.
Dr. Del Priore's prior work experience includes serving as a biotech Chief Medical Officer, a National Director at the Cancer Treatment
Centers of America (CTCA), plus faculty at Indiana University School of Medicine, Weill Cornell Medicine, and New York University School
Del Priore completed his MPH degree in Biostatistics and Epidemiology at the University of Illinois Chicago School of Public Health,
his medical degree with Distinction from The State University of New York, his BA, magna cum laude, in Philosophy, at The City University
of New York, with additional training at Memorial Sloan Kettering Cancer Center (MSKCC), The University of Chicago, Northwestern University,
and the University of Rochester. He has authored numerous publications, was named on several patents, and was listed as the "Best
Doctors" by the U.S. News & World Report. He regularly appears in various media outlets as a Key Opinion Leader (KOL) in oncology.
BriaCell Therapeutics Corp.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading
"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks
and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities
and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty
to update such information except as required under applicable law.
Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Director of Public Relations